Bristol Myers Squibb Rumored to Be Looking for a Buyer for Its Mead Johnson Division
Bristol-Myers Squibb is quietly seeking a buyer Mead Johnson division, its baby formula business 
which is estimated to be worth around $7-$9 billion. According to word on the street, BMS may have approached PepsiCo, Danone, Nestlé, Kraft and Heinz as prospective buyers. BMS has also put out feelers to pharmaceutical companies which have nutritional divisions, including Johnson & Johnson, GlaxoSmithKline and Novartis.
The search for a buyer of Mead Johnson comes less than three months after BMS said it would conduct a strategic review of both its nutritionals business and ConvaTec, its wound care products division. Both divisions are highly profitable but are not consistent with the company’s strategic goal of refocusing corporate assets on its pharmaceutical and biopharmaceutical businesses. Both companies are located in New Jersey and sale of either or both companies could have a negative impact on its fragile economy which is already reeling from inordinately high property taxes.
BMS declined to comment on the sale, but said it "continued to evaluate its strategic options with Mead Johnson and ConvaTec". The company could also decide to spin off the units to shareholders, or do nothing.
Mead Johnson is best known for its Enfamil and Enfalac range of infant formula. ConvaTec sells a variety of wound care and ostomy products.
Until next time…
Good Luck and Good Job Hunting (not New Jersey)!!!!!!
